BioSpace News Archive

LAPIX Therapeutics, Inc. (“LAPIX”) today announced the U.S. Patent & Trademark Office issued its U.S. Patent No. 11,648,225, entitled “Compositions And Methods For Reducing Immune Intolerance And Treating Autoimmune Disorders.”

Sirnaomics Ltd. has received approval of an HK$8 million subsidy from the Hong Kong Science and Technology Parks Corporation, which will be used to accelerate research and development of its leading RNAi drug candidate, STP122G, a GalNAc-based innovative anticoagulant therapeutic.

Acasti Pharma Inc. announced today that Prashant Kohli , CEO, will be participating in a Company Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference on Thursday, May 18, 2023.

Shuttle Pharmaceuticals Holdings, Inc. announced today that its Chief Executive Officer, Anatoly Dritschilo , M.D., will be participating in a Webcast and Panel Presentation at the Lytham Partners Spring 2023 Investor Conference (the “Conference”) on Thursday, May 18, 2023.

Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd., announced they will be operating under the new name Resolian — fully integrating the companies into one organization.

Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the “Company” or “Gemina”) is delighted to announce that its patented chemistry for Antibody Immobilization allows for a massive reduction in antibody usage when used in lateral flow assay (“LFA”) diagnostic tests.

CancerVAX today reported that the Company’s CEO, Ryan Davies, recently discussed the importance of developing new drugs and medical devices and their impact on the world of healthcare with biotech entrepreneur and venture capitalist Dinesh Patel.

Compare the Biomarket™, a groundbreaking clinical biosamples quotation platform, has officially launched today, promising researchers valuable insights into the clinical biosamples market and providing cost-effective solutions to accelerate scientific discovery. ™

Decibel Therapeutics (Nasdaq: DBTX) today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Barclays 2023 Gene Editing and Gene Therapy Summit on Wednesday, May 24, 2023 at 10:30 a.m. E.T being held virtually.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were unveiled in an oral presentation at the 64th American Society of Hematology (ASH) annual meeting.